Guardant Health, Inc. announced a collaboration with Boehringer Ingelheim to pursue regulatory approval and commercialization of the Guardant360 CDx liquid biopsy. This test will serve as a companion diagnostic (CDx) for zongertinib, an investigational therapy for non-small cell lung cancer (NSCLC).
The Guardant360 CDx blood test will provide comprehensive genomic profiling to identify actionable biomarkers, helping to select NSCLC patients with HER2 mutations who may be eligible for zongertinib treatment. This partnership expands the application of Guardant's technology in targeted therapy selection.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, noted that this collaboration aims to identify patients who may respond poorly to standard treatments, enabling oncologists to use a simple blood draw for precise treatment guidance. Guardant360 CDx is already FDA-approved for multiple targeted therapies in NSCLC and has broad Medicare and commercial coverage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.